Sumitomo Mitsui Trust Group Inc. Increases Stock Position in Humana Inc. (NYSE:HUM)

Sumitomo Mitsui Trust Group Inc. increased its holdings in Humana Inc. (NYSE:HUM - Free Report) by 0.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 325,409 shares of the insurance provider's stock after purchasing an additional 2,027 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned approximately 0.27% of Humana worth $103,070,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Pzena Investment Management LLC raised its position in shares of Humana by 538.7% during the second quarter. Pzena Investment Management LLC now owns 2,318,347 shares of the insurance provider's stock worth $866,250,000 after acquiring an additional 1,955,375 shares during the last quarter. Davis Selected Advisers boosted its stake in shares of Humana by 16.1% in the 2nd quarter. Davis Selected Advisers now owns 2,311,362 shares of the insurance provider's stock valued at $863,640,000 after purchasing an additional 321,233 shares during the last quarter. Marshall Wace LLP increased its position in shares of Humana by 118.9% during the second quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider's stock worth $532,564,000 after buying an additional 774,085 shares during the period. Legal & General Group Plc lifted its holdings in Humana by 2.1% in the second quarter. Legal & General Group Plc now owns 1,183,985 shares of the insurance provider's stock valued at $442,396,000 after buying an additional 24,842 shares during the period. Finally, Ontario Teachers Pension Plan Board boosted its position in Humana by 11,647.2% during the first quarter. Ontario Teachers Pension Plan Board now owns 1,059,478 shares of the insurance provider's stock valued at $367,342,000 after acquiring an additional 1,050,459 shares during the last quarter. 92.38% of the stock is owned by institutional investors.

Humana Stock Performance

Shares of NYSE HUM traded down $6.61 during midday trading on Thursday, hitting $282.81. The company's stock had a trading volume of 1,112,607 shares, compared to its average volume of 1,870,377. The firm has a market capitalization of $34.05 billion, a price-to-earnings ratio of 25.67, a P/E/G ratio of 2.21 and a beta of 0.52. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. The stock has a fifty day moving average price of $284.64 and a 200 day moving average price of $332.14. Humana Inc. has a one year low of $213.31 and a one year high of $527.18.

Humana (NYSE:HUM - Get Free Report) last posted its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.48 by $0.68. The firm had revenue of $29.30 billion for the quarter, compared to the consensus estimate of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. On average, research analysts forecast that Humana Inc. will post 15.83 EPS for the current fiscal year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be paid a dividend of $0.885 per share. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.54 annualized dividend and a yield of 1.25%. Humana's dividend payout ratio is currently 31.36%.

Wall Street Analysts Forecast Growth

HUM has been the topic of several research analyst reports. Truist Financial cut their target price on Humana from $400.00 to $260.00 and set a "hold" rating on the stock in a research report on Friday, October 11th. Wells Fargo & Company decreased their price target on shares of Humana from $387.00 to $290.00 and set an "overweight" rating for the company in a research note on Monday, November 4th. Deutsche Bank Aktiengesellschaft reduced their target price on Humana from $349.00 to $250.00 and set a "hold" rating for the company in a research note on Thursday, October 3rd. JPMorgan Chase & Co. upped their price target on Humana from $332.00 to $396.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 21st. Finally, Oppenheimer decreased their price objective on Humana from $400.00 to $280.00 and set an "outperform" rating for the company in a report on Thursday, October 3rd. Twenty research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $315.86.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.